E N Subong

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

A W Partin, M W Kattan, M. Kattan, 1997, JAMA.

Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age.

A W Partin, D. Chan, W. Catalona, 1996, Urology.

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

A W Partin, R C Flanigan, J. Richie, 1998, JAMA.

Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins.

A W Partin, A. Partin, D. S. Coffey, 1997, Urology.

Differential nuclear matrix protein expression in prostate cancers: correlation with pathologic stage.

A W Partin, A. Partin, E. N. Subong, 1998, The Journal of urology.